Acne
Actinic Keratosis
Aesthetics
Alopecia
Atopic Dermatitis
Buy-and-Bill
COVID-19
Case-Based Roundtable
Chronic Hand Eczema
Drug Watch
Eczema
General Dermatology
Hidradenitis Suppurativa
Melasma
NP and PA
Pediatric Dermatology
Pigmentary Disorders
Practice Management
Precision Medicine and Biologics
Prurigo Nodularis
Psoriasis
Psoriatic Arthritis
Rare Disease
Rosacea
Skin Cancer
Vitiligo
Wound Care

Level Up: Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to Severe Atopic Dermatitis: Results of an Open-label, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study : Episode 4

Opinion

Video

September 12, 2024

Comprehensive Analysis: Upa Outshines Dupi Across Key Measures

Author(s):

Christopher G. Bunick, MD, PhD,Raj Chovatiya, MD, PhD, MSCI

Dermatology experts analyze the superior outcomes of upadacitinib compared with dupilumab across key efficacy measures in atopic dermatitis treatment.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Evaluating Treatment Efficacy: Identifying and Managing AD Flares in Systemic Therapy Patients

EP: 2.Composite Scores and Quality of Life: A New Standard for AD Management

EP: 3.From Trial to Practice: Applying Study Results to Real-World AD Management

Now Viewing

EP: 4.Comprehensive Analysis: Upa Outshines Dupi Across Key Measures

EP: 5.From Clinic to Practice: Translating AD Trial Data

EP: 6.Final Thoughts: The Importance of Comparative Studies in AD

EP: 7.Improved Quality of Life: Upadacitinib's Role in Managing AD

EP: 8.Experts Delve Into Upadacitinib vs Dupilumab: Insights From LEVEL UP

Related Videos

Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies

Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children

Supporting Caregivers in Successful Long-Term Atopic Dermatitis Management: The Role of Dermatologists

Challenges and Emerging Solutions in Treatment for Age Groups: Addressing Disease Control, Safety, and Usability

Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis

Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma

Differentiating Between JAK Inhibitors in Clinical Practice

IL-17 Inhibitor Treatment Impact on Quality of Life in Psoriasis and Psoriatic Arthritis

Clinical Attributes of IL-17 Inhibitors in Psoriasis

Laboratory Monitoring with Oral JAK Inhibitors